Clinical Trial

Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-28; most recent amendment 2026-07-23.
Status change: Not Yet Recruiting → Recruiting 2024-09-28
Trial Details
NCT Number NCT06577519
Lead Sponsor Jiangsu vcare pharmaceutical technology co., LTD
Conditions Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Enrollment 1,000 participants
Start Date 2024-09-06
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-27